Overview

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Panobinostat